BCL2 and brain cancer: It was also shown that CD133-positive brain cancer stem cells expressed a high level of BCL-2 upon TRAIL induction, and a knockdown of BCL-2 subsequently enhanced the sensitivity of the CSCs to TRAIL-mediated inhibition [166].